4D Pharma

4D Pharma is engaged in research and development of pharmaceutical products in live biotherapeutic areas.
  • TickerDDDD
  • ISINGB00BJL5BR07
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom
Olga Smolentseva

4D PHARMA (CORPORATE, TP 407p) | Clinical collaboration with Merck KGaA to pave the way in UC

4D PHARMA (CORPORATE, TP 407p) | Clinical collaboration with Merck KGaA to pave the way in UC

Olga Smolentseva

4D PHARMA: Presentations at SITC 2020 highlight the proposed MoA of MRx0518 | CORPORATE | 407p(+267%)

4D PHARMA - CORPORATE | 407p(+267%) Presentations at SITC 2020 highlight the proposed MoA of MRx0518 MRx0518 induces immunologic changes in cancer patients MRx0518 shows strong immuno-modulatory activity in BC Phase I/II of MRx0518 plus Keytruda to include additional cancer types

Olga Smolentseva

4D PHARMA (CORPORATE, TP 407p) | Presentations at SITC support MRx0518 development:

4D PHARMA (CORPORATE, TP 407p) | Presentations at SITC support MRx0518 development:

Olga Smolentseva

4D PHARMA (CORPORATE, FV 407p) | Proposed merger to extend cash runway and provide access to US funds

4D PHARMA (CORPORATE, FV 407p) | Proposed merger to extend cash runway and provide access to US funds

Olga Smolentseva

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D Blautix showed encouraging activity on bowel habit in IBS patients Blautix could be well positioned in IBS-M Anticipating the full data to be released by the end of 2020

Olga Smolentseva

4D PHARMA (CORPORATE, TP 407p) | Presentations at SITC support MRx0518 development:

4D PHARMA (CORPORATE, TP 407p) | Presentations at SITC support MRx0518 development:

Olga Smolentseva

4D PHARMA (CORPORATE, TP 407p) | Clinical collaboration with Merck KGaA to pave the way in UC

4D PHARMA (CORPORATE, TP 407p) | Clinical collaboration with Merck KGaA to pave the way in UC

Olga Smolentseva

4D PHARMA: Presentations at SITC 2020 highlight the proposed MoA of MRx0518 | CORPORATE | 407p(+267%)

4D PHARMA - CORPORATE | 407p(+267%) Presentations at SITC 2020 highlight the proposed MoA of MRx0518 MRx0518 induces immunologic changes in cancer patients MRx0518 shows strong immuno-modulatory activity in BC Phase I/II of MRx0518 plus Keytruda to include additional cancer types

Olga Smolentseva

4D PHARMA (CORPORATE, FV 407p) | Proposed merger to extend cash runway and provide access to US funds

4D PHARMA (CORPORATE, FV 407p) | Proposed merger to extend cash runway and provide access to US funds

Olga Smolentseva

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D

4D PHARMA CORPORATE | 407p Blautix topline data show positive trends in both IBS-C and IBS-D Blautix showed encouraging activity on bowel habit in IBS patients Blautix could be well positioned in IBS-M Anticipating the full data to be released by the end of 2020

Olga Smolentseva

4D PHARMA (CORPORATE, FV 407p) | Cash runway sufficient to support potential clinical catalysts in 2H20 :

4D PHARMA (CORPORATE, FV 407p) | Cash runway sufficient to support potential clinical catalysts in 2H20 :

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch